|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also found that the expression of amphiregulin, a member of the epidermal growth factor (EGF) family, was correlated with IL13Rα2 expression in cultured melanoma cells, xenograft tumour tissues and melanoma clinical samples.
|
30718742 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the pathogenesis of cutaneous melanoma is poorly understood, increasing evidence shows that epidermal growth factor (EGF) may be involved.
|
30569717 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to evaluate the utility of osteoprotegerin (OPG), osteopontin (OPN), epidermal growth factor (EGF) and vascular endothelial growth factor VEGF for the diagnosis and prognosis of melanoma.
|
30061268 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, a theoretical model is developed to describe the percutaneous siRNA delivery mediated by SPACE-EGF to melanoma and the growth inhibition of melanoma.
|
28349327 |
2017 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that EGF G1380A and bFGF C754G gene polymorphisms were associated with the susceptibility and prognosis of malignant melanoma, and that the polymorphisms of EGF G1380A and bFGF C754G as well as the haploid TAG increased the susceptibility of malignant melanoma.
|
28219779 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER-3 - one of the four member of the tyrosin kinase epidermal growth factor receptors (EGFRs) family- is frequently overexpressed in solid tumors, including melanoma.
|
29221137 |
2017 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS are the two most frequent oncogenic driver mutations in melanoma and are pivotal components of both the EGF and FGF signaling network.
|
25749811 |
2015 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analyses results suggest that the XPD gene, but not the EGF gene, has contributed to CM susceptibility, and XPD is a possible drug target.
|
25537294 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This points to HER4 as an important receptor in malignant melanoma and also raises the question of whether the other receptors in the EGF system could be involved.
|
24366194 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stable EGF knockdown (EGFkd) in EGF-high (M24met) and EGF-low (A375) expressing melanoma cells was generated.
|
22951723 |
2013 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this meta-analysis indicates that EGF +61A>G polymorphism might not be a primary determinant in melanoma development and progression; EGF gene might be expected to interact with other genes in different signaling pathways to initiate and promote the carcinogenic process.
|
23201894 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C.
|
22951722 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
|
23242808 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of both EGF receptor and AKT sensitized treatment-resistant BRAF mutant melanoma cultures to vemurafenib.
|
23239741 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of endogenous RasGRP3 expression in these melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth factor (EGF) stimulation.
|
21602881 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using RNAi this EGFR activation was further shown to depend on the metalloproteases ADAM9 and ADAM17 in SCC-9 cells. cDNA array hybridization and RT-PCR analysis showed overexpression of a Disintegrin and a Metalloproteases (ADAMs) and EGF family proligands in melanoma cell lines.
|
19003995 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of RaLP in melanoma signal transduction pathways revealed that (a) when ectopically expressed in RaLP-negative melanocytes and nonmetastatic melanoma cells, it functions as a substrate of activated insulin-like growth factor-1 and epidermal growth factor receptors and increases Ras/mitogen-activated protein kinase (MAPK) signaling and cell migration, whereas (b) its silencing in RaLP-positive melanoma cells abrogates cell migration in vitro, without affecting MAPK signaling, suggesting that RaLP activates both Ras-dependent and Ras-independent migratory pathways in melanomas.
|
17409413 |
2007 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma.
|
16691190 |
2006 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is the second study to find no association between EGF +61 and melanoma susceptibility.
|
15373781 |
2004 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data do not support a significant association between melanoma and the EGF 61*G allele or the homozygous G/G genotype.
|
15087376 |
2004 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between functional polymorphism in EGF gene and malignant melanoma.
|
11844511 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a comparative analysis, CD31 was not expressed by any of the melanoma cell lines, whereas TIE-1 (tyrosine kinase with Ig and epidermal growth factor homology domains-1) was strongly expressed in the highly aggressive tumor cells with a low level of expression in one of the poorly aggressive cell lines.
|
11416160 |
2001 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcripts of c-myb and the beta-NGF gene were not detectable in any of the melanoma cell lines, whereas sis- and epidermal growth factor (EGF) receptor gene-specific transcripts were present in two and four melanoma cell lines, respectively.
|
8471834 |
1993 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither neutralizing antisera to PDGF or TGF- alpha nor a monoclonal antibody to the epidermal growth factor (EGF)-receptor inhibited melanoma cell growth.
|
2056188 |
1991 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recombination sites involved the N-ras and the epidermal growth factor gene in the melanomas.
|
2293915 |
1990 |